PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence

Authors

  • Paula Lapa Serviço de Medicina Nuclear. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • Rodolfo Silva Serviço de Medicina Nuclear. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • Tiago Saraiva Serviço de Medicina Nuclear. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • Arnaldo Figueiredo Serviço de Urologia. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • Rui Ferreira Serviço de Medicina Nuclear. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • Gracinda Costa Serviço de Medicina Nuclear. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • João Pedroso Lima Serviço de Medicina Nuclear. Centro Hospitalar e Universitário de Coimbra. Coimbra.

DOI:

https://doi.org/10.20344/amp.7056

Keywords:

Fluorocholine, Positron-Emission Tomography, Prostatic Neoplasms, Radiopharmaceuticals.

Abstract

Introduction: In prostate cancer, after therapy with curative intent, biochemical recurrence frequently occurs. The purpose of this study was to evaluate the impact of PET/CT with 18F-fluorocholine in restaging these patients and in their orientation, and to analyze the effect of the risk stratification, the values of PSA and the hormone suppression therapy, in the technique sensitivity.
Material and Methods: Retrospective analysis of 107 patients with prostate carcinoma in biochemical recurrence who underwent PET/CT with 18F-fluorocholine in our hospital, between December 2009 and May 2014.
Results: The overall sensitivity was 63.2% and 80.0% when PSA > 2 ng/mL. It was possible to identify distant disease in 28% of the patients. The sensitivity increased from 40.0%, in patients with low and intermediate risk, to 55.2% in high-risk patients. Without hormonal suppression therapy, the sensitivity was 61.8%, while in the group under this therapy, was 67.7%.
Discussion: PET/CT with 18F-fluorocholine provided important information even in patients with low levels of PSA, however, with significantly increased sensitivity in patients with PSA > 2 ng/mL. Sensitivity was higher in high-risk patients compared with low and intermediate risk patients, however, without a statistically significant difference. The hormone suppression therapy does not appear to influence uptake of 18F-fluorocholine in patients resistant to castration.
Conclusions: In this study, PET/CT with 18F-Fluorocholine showed good results in restaging patients with prostate cancer biochemical recurrence, distinguishing between loco regional and systemic disease, information with important consequences in defining the therapeutic strategy.

Downloads

Download data is not yet available.

Author Biography

Paula Lapa, Serviço de Medicina Nuclear. Centro Hospitalar e Universitário de Coimbra. Coimbra.

Dt.Nascimento: 19/06/1970 Dt.Formatura: 28/11/1994  Dt.Inscrição: 12/12/1994

Dt. Obtenção: 21/11/2001  Dt. Inscrição: 21/11/2001

 

 

Published

2016-03-31

How to Cite

1.
Lapa P, Silva R, Saraiva T, Figueiredo A, Ferreira R, Costa G, Lima JP. PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence. Acta Med Port [Internet]. 2016 Mar. 31 [cited 2024 Mar. 29];29(3):182-9. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7056

Issue

Section

Original